Log In
Print
BCIQ
Print
Print this Print this
 

velaptasvir (GS-5816)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionPan-genotypic HCV NS5A inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotype 1 infection; Treat HCV infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today